<DOC>
	<DOCNO>NCT00402038</DOCNO>
	<brief_summary>To determine efficacy subcutaneous MNTX relieve opioid-induced constipation patient advance medical illness .</brief_summary>
	<brief_title>Study Methylnaltrexone ( MNTX ) Relief Constipation</brief_title>
	<detailed_description>This multi-center , double-blind , randomize parallel group study conduct patient advanced medical illness opioid-induced constipation . Eligible patient randomly assign receive SC dose either MNTX , dose 1 placebo every day 2 week . At Day 8 , eligible patient , allow , could escalate high dose MNTX .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>18 year age older Negative pregnancy test ( serum urine ) screen woman childbearing potential Advanced Medical Illness ( i.e. , terminal illness , incurable cancer end stage AIDS ) life expectancy â‰¥ 1 month patient must sign ICF Women pregnant and/or nurse Previous treatment MNTX Participation study involve investigational product within 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>